The use of bone turnover markers for monitoring the treatment of osteoporosis in postmenopausal females undergoing total knee arthroplasty: a prospective randomized study

Table 2 Medication duration and adverse reactions of treatment in the BTM monitoring group and the control group

	Monitoring group (n = 28)	Control group (n = 29)	p value
Alendronate duration (days)	236 ± 71	90 ± 0	0.000
Calcitriol + Ca duration (days)	214 ± 72	90 ± 0	0.000
Total medication duration (days)	259 ± 72	90 ± 0	0.000
Adverse reaction	5 (17.9%)^a	2 (6.9%)^b	0.392

Ca calcium
^aThree patients had gastrointestinal reaction and two patients had muscular soreness
^bOne patient had gastrointestinal reaction and one patient had headache

ISSN: 1749-799X